TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31916540

Group type: EXPERIMENTAL
Intervention: Purified CBD (Epidiolex/Epidyolex; >99% CBD)
Number of subjects: 0
Study: 31302043

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4735

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4735
Study: 28653328

Group type: EXPERIMENTAL
Intervention: Filling pressure of 40 mm Hg (group 1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Filling pressure of 60 mm Hg (group 2)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Filling pressure of 80 mm Hg (group 3; control)
Number of subjects: 240
Study: 27094610

Group type: EXPERIMENTAL
Intervention: Roxadustat (FG-4592)
Number of subjects: 145
Study: 25458329

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 34

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 34
Study: 22093134

Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGV) 900 mg b.i.d. for 7 days followed by 900 mg daily for up to 21 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ganciclovir (GCV) 5 mg/kg b.i.d. for 7 days followed by daily GCV 5 mg/kg for up to 21 days
Number of subjects: 37
Study: 19233252

Group type: EXPERIMENTAL
Intervention: Cochlear microphonic potential (CM) recorded by extratympanic electrocochleography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distortion-product otoacoustic emissions (OAEs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cochlear microphonic potential (CM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distortion-product OAEs and CM monitored in gerbils during intracranial pressure changes
Number of subjects: 0
Study: 17466917

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (in vitro sensitivity measurement)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Rhodamine 123 (Rh123) extrusion measurement
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Dexamethasone (in vitro resistance measurement)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ABCB1 gene polymorphisms assessment
Number of subjects: 74
Study: 15089791

Group type: EXPERIMENTAL
Intervention: Structured Treatment and Teaching Programme (STTP) combining dietary freedom with insulin adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard practice for treatment of Type 1 diabetes
Number of subjects: 0
Study: 12547241

Group type: EXPERIMENTAL
Intervention: Iron sucrose complex therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral iron administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory parameters (ferritin, transferrin saturation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-reactive protein level
Number of subjects: 0
Study: 9440474

Group type: EXPERIMENTAL
Intervention: rhIGF-I (40 microg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rhIGF-I
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rhIGF-I and Placebo
Number of subjects: 9
Study: 7662901

Group type: EXPERIMENTAL
Intervention: L‐NAME (NO synthase inhibitor) at doses of 40 micrograms kg‐1 injected plus 50 micrograms kg‐1 infused i.v.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) 10 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone (TRH) 200 micrograms i.v.
Number of subjects: 7
Study: 3385105

Group type: EXPERIMENTAL
Intervention: Training with household measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with food models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined trained groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 0
Study: 30270800

Group type: EXPERIMENTAL
Intervention: Aminophylline 250 mg intravenously
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study: 25401685

Group type: EXPERIMENTAL
Intervention: Challenge condition (vignette that challenges belief in a just world)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Control conditions (vignettes that confirm or do not attempt to influence belief in a just world)
Number of subjects: 1041
Study: 23261785

Group type: EXPERIMENTAL
Intervention: Onset of reaching
Number of subjects: 0
Study: 16527227

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5%
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Topical indomethacin 0.1%
Number of subjects: 62

Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: All treatments (ketorolac, indomethacin, artificial tears)
Number of subjects: 62
Study: 12617689

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS) (<0.1 W/cm(2))
Number of subjects: 0
Study: 10371400

Group type: COMPARATOR
Intervention: Ethanol 0.0 g/kg (Control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ethanol 0.8 g/kg
Number of subjects: 18
Study: 8660070

Group type: EXPERIMENTAL
Intervention: Intensive induction therapy with additional intensification treatment (two blocks of intensification)
Number of subjects: 1612

Group type: COMPARATOR
Intervention: No intensification treatment
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Intensive induction therapy
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Intensification treatment
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Bone marrow transplant (BMT)
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Children with Down's syndrome
Number of subjects: 1612
Study: 1997060

Group type: EXPERIMENTAL
Intervention: Propofol as an anaesthetic induction agent
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control subjects (21 subjects)
Number of subjects: 13
Study: 6337412

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nadolol 160 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sotalol 160 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg
Number of subjects: 22
Study: 30670282

Group type: EXPERIMENTAL
Intervention: Complementary medicine (CAM) use
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Higher levels of social support
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Lower health literacy skills
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Higher health literacy relating to engaging with health care providers
Number of subjects: 153

Group type: COMPARATOR
Intervention: Decision-making self-efficacy
Number of subjects: 153
Study: 27881395

Group type: EXPERIMENTAL
Intervention: Dietary weight-loss group (calorie-restricted diet for 6 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No-weight loss control group (maintained habitual diet and physical activity levels)
Number of subjects: 54
Study: 25792086

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 5 g b.i.d. and CoQ10 100 mg t.i.d. orally
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 22781136

Group type: EXPERIMENTAL
Intervention: PR plus SSRT
Number of subjects: 19

Group type: COMPARATOR
Intervention: PR alone
Number of subjects: 19
Study: 20628304

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Waist-to-Hip Ratio (WHR)
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Receiver Operating Characteristic Curve
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Relative Integrated Discrimination Improvement Statistic
Number of subjects: 11140
Study: 19076960

Group type: EXPERIMENTAL
Intervention: Seeing the screen
Number of subjects: 157

Group type: COMPARATOR
Intervention: Not seeing the screen
Number of subjects: 157
Study: 17509259

Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scanning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical recommendations for PET scans
Number of subjects: 0
Study: 14702590

Group type: EXPERIMENTAL
Intervention: Promotional materials (labels)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Promotional materials (labels plus signs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no promotional materials)
Number of subjects: 10
Study: 11464149

Group type: EXPERIMENTAL
Intervention: Stated willingness to participate (WTP)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Knowledge of basic vaccine trial concepts
Number of subjects: 610
Study: 9336506

Group type: EXPERIMENTAL
Intervention: Aztreonam and Vancomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipenem and Cilastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage fluid analysis
Number of subjects: 0
Study: 8178250

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 132
Study: 3228990

Group type: COMPARATOR
Intervention: 5% cocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emla (lignocaine and prilocaine mixture)
Number of subjects: 0
Study: 29606370

Group type: EXPERIMENTAL
Intervention: Nurse-led group discussions
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 170
Study: 28971609

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three tested coffees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 26643109

Group type: EXPERIMENTAL
Intervention: Eviprostat (two capsules, q 8 h) for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pollen extract (Cernilton) (two capsules, q 8 h) for 8 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Eviprostat
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pollen extract
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Eviprostat and Pollen extract
Number of subjects: 100
Study: 24250291

Group type: EXPERIMENTAL
Intervention: Interval training program (work: rest ratio of 1:1, 8 weeks, 45-60 minutes, 60-79% of HR max)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (sedentary during the 8 weeks)
Number of subjects: 245
Study: 20848374

Group type: EXPERIMENTAL
Intervention: Structured discharge planning intervention
Number of subjects: 241
Study: 18440315

Group type: COMPARATOR
Intervention: Continuation of immunosuppressives (Con)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Discontinuation of immunosuppressives (Dis)
Number of subjects: 80
Study: 16531926

Group type: EXPERIMENTAL
Intervention: I‐FP‐CIT SPECT imaging in Parkinson's disease
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: I‐FP‐CIT SPECT imaging in PSP
Number of subjects: 56

Group type: COMPARATOR
Intervention: Comparison of I‐FP‐CIT SPECT imaging between Parkinson's disease and PSP
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Asymmetric index (AI) in Parkinson's disease
Number of subjects: 56
Study: 14629883

Group type: EXPERIMENTAL
Intervention: Diathermy (group 2)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Scalpel (group 1)
Number of subjects: 32
Study: 10907942

Group type: EXPERIMENTAL
Intervention: 30 mg/day tamoxifen
Number of subjects: 494

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 494
Study: 9195356

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Succinylcholine 1 mg/kg
Number of subjects: 42
Study: 1356922

Group type: EXPERIMENTAL
Intervention: Low-alcohol beer (alcohol restriction)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Caloric intake reduction (4,200-6,300 kJ/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Normal alcohol intake (control)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual diet (control)
Number of subjects: 86
Study: 2865148

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg (chronic administration for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg (chronic administration for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg (chronic administration for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol and Atenolol (multisubject comparison)
Number of subjects: 0
Study: 31228861

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion system (CIIS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Multiple daily insulin administrations (MDI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both CIIS and MDI
Number of subjects: 48
Study: 29727385

Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA) 6g thrice daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA)
Number of subjects: 150
Study: 26649938

Group type: EXPERIMENTAL
Intervention: High-dose prolonged magnesium sulfate infusion (50 mg/kg/hr for 4 hours)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bolus magnesium sulfate (50 mg/kg over 1 hour)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-dose prolonged magnesium sulfate infusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bolus magnesium sulfate
Number of subjects: 38
Study: 24506775

Group type: COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution 0.2% administered three times a day for 1 day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate gel 0.07% applied twice daily for 29 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate gel 0.18% applied once daily for 29 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate gel 0.18% applied twice daily for 29 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate gel 0.5% applied once daily for 29 days
Number of subjects: 0
Study: 22686073

Group type: COMPARATOR
Intervention: Benazepril (10 mg/d) in the Western medicine group (WM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chinese medicine treatment by syndrome typing in the Chinese medicine group (CM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination of Benazepril and Chinese herbs in the combination group
Number of subjects: 60
Study: 20511580

Group type: EXPERIMENTAL
Intervention: Telephone booster intervention (weekly reinforcement of clinic advice)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study: 17606976

Group type: EXPERIMENTAL
Intervention: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by extended-field radiotherapy (EF-RT)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Extended-field radiotherapy (EF-RT) alone
Number of subjects: 650

Group type: COMPARATOR
Intervention: Treatment of relapse after EF-RT
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Incidence of second malignancies
Number of subjects: 650
Study: 16267763

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate with abacavir/lamivudine
Number of subjects: 340

Group type: COMPARATOR
Intervention: Efavirenz with abacavir/lamivudine
Number of subjects: 340
Study: 12131112

Group type: EXPERIMENTAL
Intervention: AMR 15 group (15 microg x kg(‐1) x min(‐1) amrinone with a 1.0‐mg/kg loading dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ReAMR group (5 microg x kg(‐1) x min(‐1) amrinone with 1.0‐mg/kg loading and reloading doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no amrinone)
Number of subjects: 30
Study: 10343521

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SSZ) 2-3 g/day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5-15 mg/week
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combination of Sulphasalazine and Methotrexate (COMBI) same dose range as above
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients homozygous for the C677T mutation in MTHFR gene
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients heterozygous for the C677T mutation in MTHFR gene
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with gastrointestinal toxicity
Number of subjects: 105

Group type: COMPARATOR
Intervention: Clinical efficacy variables
Number of subjects: 105
Study: 7856896

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (50-100 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous fentanyl (50-100 micrograms)
Number of subjects: 20
Study: 1974395

Group type: EXPERIMENTAL
Intervention: Priming with vecuronium (0.01 mg/kg priming dose, 4‐min priming interval, 0.14‐mg/kg intubating dose along with thiopental 4‐6 mg iv)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Timing with vecuronium (0.15‐mg/kg intubating dose given before thiopental and timed to weakness of hand grip)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.5 mg/kg)
Number of subjects: 60
Study: 7400477

Group type: EXPERIMENTAL
Intervention: Flunisolide, 50 micrograms four times per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31929136

Group type: EXPERIMENTAL
Intervention: Breathing and segmental stabilization exercises (RE+LSSE)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Segmental stabilization exercises (LSSE)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Modality treatment (Control)
Number of subjects: 59
Study: 29576128

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing without leak (SB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spontaneous breathing with calibrated air leak (SB-leak)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation with calibrated leak (PPV-leak)
Number of subjects: 20
Study: 28556586

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 417
Study: 26142575

Group type: EXPERIMENTAL
Intervention: Sexual intercourse 3-4 times a week
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/d
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard medical therapy alone (Control)
Number of subjects: 75
Study: 24104790

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg tablet orally up to five doses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous labetalol (escalating doses of 20, 40, 80, 80, and 80 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous labetalol
Number of subjects: 60
Study: 21221853

Group type: EXPERIMENTAL
Intervention: Panitumumab-based therapy (PBT)
Number of subjects: 2115
Study: 18413818

Group type: EXPERIMENTAL
Intervention: Aspirin exposure with ODC 316AA genotype
Number of subjects: 2207

Group type: EXPERIMENTAL
Intervention: Aspirin exposure with homozygous ODC 316AA genotype
Number of subjects: 2207

Group type: EXPERIMENTAL
Intervention: Aspirin exposure with wild-type or heterozygous genotypes
Number of subjects: 2207

Group type: EXPERIMENTAL
Intervention: Aspirin exposure with both ODC 316AA genotype
Number of subjects: 2207
Study: 16580520

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1058
Study: 12213665

Group type: EXPERIMENTAL
Intervention: Iopanoic acid (IOP) for 7 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Saturated solution of potassium iodide (SSKI) for 10-15 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of IOP and SSKI
Number of subjects: 14
Study: 9828818

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry using HMB‐45 antibody
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: RT‐PCR for tyrosinase
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine histology
Number of subjects: 32
Study: 8133366

Group type: COMPARATOR
Intervention: Closed reduction with a median of 4 weeks of maxillomandibular fixation
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Surgical repositioning and transosseous wiring of the dislocated condylar fragment with a median of 6 weeks of maxillomandibular fixation
Number of subjects: 101
Study: 2696850

Group type: EXPERIMENTAL
Intervention: R 76713 (5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: R 76713 (10 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: R 76713 (20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 4887385

Group type: EXPERIMENTAL
Intervention: Phenformin (up to 300 mg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metformin (up to 3 g daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Phenformin and Metformin (combined)
Number of subjects: 90
Study: 7189149

Group type: EXPERIMENTAL
Intervention: Morning types (M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evening types (E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circadian trends in correct rejection levels and body temperature for E types
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circadian trends in correct rejection levels and body temperature for M types
Number of subjects: 0
Study: 30874252

Group type: EXPERIMENTAL
Intervention: Resin infiltration technique (Icon)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Self‐assembling peptide (Curodont Repair)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluoride varnish application (Duraphat)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (regular brushing)
Number of subjects: 21
Study: 30130715

Group type: EXPERIMENTAL
Intervention: Alcohol and marijuana co-use (AM)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Alcohol only (AO)
Number of subjects: 277
Study: 26769303

Group type: EXPERIMENTAL
Intervention: MK‐8389 (oral doses once daily for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (oral doses once daily for 14 days)
Number of subjects: 0
Study: 24961184

Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 84

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 84